Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$85.87 +0.4%	$78.56	$61.24 ▼ $86.57	$265.14B	0.36	5.13 million shs	3.49 million shs
BNTX BioNTech	$106.06 +0.9%	$104.72	$81.20 ▼ $129.27	$25.28B	1.45	1.11 million shs	704,314 shs
MRNA Moderna	$27.34 -0.7%	$26.06	$23.15 ▼ $59.73	$10.76B	2.01	12.29 million shs	6.06 million shs
PFE Pfizer	$26.27 -0.6%	$24.76	$20.92 ▼ $30.43	$150.27B	0.55	62.68 million shs	47.61 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.21%	+15.32%	+4.64%	+22.09%	+10.35%
BNTX BioNTech	-0.31%	+7.20%	-6.49%	-5.82%	-14.28%
MRNA Moderna	-3.33%	+8.72%	+9.55%	-15.37%	-54.25%
PFE Pfizer	-3.34%	+10.95%	+6.42%	+3.28%	-7.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$85.87 +0.4%	$78.56	$61.24 ▼ $86.57	$265.14B	0.36	5.13 million shs	3.49 million shs
BNTX BioNTech	$106.06 +0.9%	$104.72	$81.20 ▼ $129.27	$25.28B	1.45	1.11 million shs	704,314 shs
MRNA Moderna	$27.34 -0.7%	$26.06	$23.15 ▼ $59.73	$10.76B	2.01	12.29 million shs	6.06 million shs
PFE Pfizer	$26.27 -0.6%	$24.76	$20.92 ▼ $30.43	$150.27B	0.55	62.68 million shs	47.61 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.21%	+15.32%	+4.64%	+22.09%	+10.35%
BNTX BioNTech	-0.31%	+7.20%	-6.49%	-5.82%	-14.28%
MRNA Moderna	-3.33%	+8.72%	+9.55%	-15.37%	-54.25%
PFE Pfizer	-3.34%	+10.95%	+6.42%	+3.28%	-7.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.80	Moderate Buy	$86.00	0.15% Upside
BNTX BioNTech	2.64	Moderate Buy	$134.46	26.78% Upside
MRNA Moderna	2.00	Hold	$41.81	52.94% Upside
PFE Pfizer	2.37	Hold	$28.41	8.15% Upside

Current Analyst Ratings Breakdown

Latest AZN, PFE, BNTX, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/3/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$28.00 ➝ $30.00
10/1/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$28.00
9/27/2025	AZN AstraZeneca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/27/2025	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$116.00 ➝ $121.00
9/8/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$136.00
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$18.00 ➝ $15.00
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$138.00 ➝ $136.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$25.00 ➝ $26.00

(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.93	$6.32 per share	13.58	$13.18 per share	6.52
BNTX BioNTech	$2.98B	8.56	N/A	N/A	$87.61 per share	1.21
MRNA Moderna	$3.24B	3.30	N/A	N/A	$28.33 per share	0.97
PFE Pfizer	$63.63B	2.35	$4.33 per share	6.06	$15.62 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.66	32.28	17.17	1.57	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.97	8.67	0.86	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest AZN, PFE, BNTX, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
11/3/2025	Q3 2025	BNTX BioNTech	$0.57	N/A	N/A	N/A	$1.21 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$1.01	1.18%	N/A	37.97%	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.55%	N/A	91.49%	16 Years

Latest AZN, PFE, BNTX, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.55	0.86	0.67
BNTX BioNTech	0.01	8.61	8.48
MRNA Moderna	N/A	3.93	3.77
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BNTX BioNTech	15.52%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BNTX BioNTech	19.20%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
MRNA Moderna	5,800	390.58 million	346.28 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

AZN, PFE, BNTX, and MRNA Headlines

Recent News About These Companies

Life sciences sentiment rises as Pfizer deal eases tariff concerns

October 7 at 12:32 PM | proactiveinvestors.com

Down 50%, Should You Buy the Dip on Pfizer?

October 7 at 10:10 AM | fool.com

Down 50%, Should You Buy the Dip on Pfizer?

October 7 at 10:03 AM | fool.com

TrumpRx Brings Pfizer Into the Green-Is It a Buy?

October 7 at 9:37 AM | msn.com

Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers

October 7 at 9:11 AM | talkmarkets.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)

October 7 at 8:16 AM | zacks.com

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

...

October 7 at 7:04 AM | marketbeat.com

Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer

October 7 at 6:30 AM | latimes.com

KLP Kapitalforvaltning AS Purchases 289,900 Shares of Pfizer Inc. $PFE

October 7 at 6:29 AM | marketbeat.com

SteelPeak Wealth LLC Has $6.24 Million Stake in Pfizer Inc. $PFE

October 7 at 5:33 AM | marketbeat.com

Belpointe Asset Management LLC Has $2.92 Million Stock Holdings in Pfizer Inc. $PFE

October 7 at 5:06 AM | marketbeat.com

Merit Financial Group LLC Has $5.04 Million Stock Holdings in Pfizer Inc. $PFE

October 7 at 4:34 AM | marketbeat.com

Pfizer Inc. $PFE Stake Cut by Simplicity Wealth LLC

October 7 at 4:22 AM | marketbeat.com

Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500

October 7 at 3:15 AM | fool.com

Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)

October 7 at 2:31 AM | seekingalpha.com

Pfizer (NYSE:PFE) Shares Down 3.4% - Time to Sell?

October 6 at 11:00 PM | marketbeat.com

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal (PFE)

...

October 6 at 7:34 PM | marketbeat.com

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

...

October 6 at 2:21 PM | marketbeat.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

October 6 at 1:11 PM | zacks.com

3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

October 6 at 12:04 PM | 247wallst.com

3 High-Yield Dividend Stocks to Buy in October

October 6 at 10:32 AM | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, PFE, BNTX, and MRNA Company Descriptions

AstraZeneca NASDAQ:AZN

$85.87 +0.38 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$86.00 +0.13 (+0.15%)

As of 07:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BioNTech NASDAQ:BNTX

$106.06 +0.90 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$105.55 -0.51 (-0.48%)

As of 05:38 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna NASDAQ:MRNA

$27.34 -0.20 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$27.30 -0.04 (-0.13%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$26.27 -0.16 (-0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$26.26 0.00 (-0.02%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, PFE, BNTX, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, PFE, BNTX, and MRNA Earnings

Compare Dividends

Latest AZN, PFE, BNTX, and MRNA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, PFE, BNTX, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, PFE, BNTX, and MRNA Company Descriptions

AstraZeneca NASDAQ:AZN

BioNTech NASDAQ:BNTX

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools